James Andrews, MD
Sleep Medicine · Memphis, TNNPI 1255312336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by GSK at 33.0% of the total.
Across 265 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$391
- Inspire Medical Systems, Inc.$291
- Insmed, Inc.$275
- Genentech USA, Inc.$234
- AstraZeneca$176
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,06899%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 117 | $1,356 |
| AbbVie(2 entities) | 24 | $391 |
| Inspire Medical Systems, Inc. | 2 | $291 |
| Insmed, Inc. | 15 | $275 |
| Genentech USA, Inc. | 16 | $234 |
| AstraZeneca | 14 | $176 |
| Actelion Pharmaceuticals US, Inc. | 9 | $139 |
| Philips North America LLC | 6 | $137 |
| Boehringer Ingelheim | 9 | $137 |
| United Therapeutics Corporation | 4 | $92 |
| Mallinckrodt Hospital Products Inc. | 5 | $89 |
| Sanofi | 3 | $77 |
| Mylan Specialty L.p. | 6 | $76 |
| Grifols USA, LLC | 4 | $74 |
| Sunovion Pharmaceuticals Inc. | 4 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Fisher & Paykel Healthcare Inc | 2 | $52 |
| Lilly USA, LLC | 3 | $47 |
| Harmony Biosciences LLC | 2 | $43 |
| CSL Behring | 2 | $40 |
| Merck | 2 | $32 |
| Pfizer | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Pylant Medical | 1 | $27 |
| Novartis | 2 | $25 |
| Cumberland Pharmaceuticals, Inc. | 2 | $25 |
| Verona Pharma, Inc. | 1 | $21 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$291
How this compares
$4,108 in reported general payments places this provider in the 75th percentile of 41 sleep medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $219,770 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 190 | $163,008 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 132 | $100,626 |
| NucalaMepolizumab | 13 | $47,819 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $33,317 |
| Spiriva RespimatTiotropium Bromide | 43 | $24,162 |
| Spiriva HandihalerTiotropium Bromide | 29 | $20,713 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $18,882 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $10,900 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 61 | $10,763 |
| BreynaBudesonide/Formoterol Fumarate | 38 | $7,228 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 280 | $6,410 |
| XareltoRivaroxaban | 11 | $6,072 |
| Arnuity ElliptaFluticasone Furoate | 14 | $5,908 |
| Ventolin HfaAlbuterol Sulfate | 67 | $5,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $137 | $254,83273 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,356 | $250,052289 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $176 | $119,508179 claims |
| Johnson & JohnsonXarelto | $11 | $6,07211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 41 sleep medicine providers in Tennessee.
Other sleep medicine in Memphis
- Merrill WiseMemphis$7K
- William MariencheckMemphis$3K
- Syed ZaidiMemphis$1K
- Ariel LongMemphis$828
- John McGeheeMemphis$17
- Bijoy JohnBrentwood$38K
- Kelly CardenNashville$24K
- Martha HagamanFranklin$20K
- John DenglerJohnson City$19K
- Prashant JamesKnoxville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.